Tafamidis Meglumine Capsule

TAFAMIDIS

Tafamidis is a small-molecule pharmaceutical agent that acts as a selective stabilizer of transthyretin (TTR). Its primary therapeutic action is to kinetically stabilize the native tetrameric structure of the TTR protein, thereby inhibiting its dissociation into misfolded monomers�the rate-limiting step in the formation of amyloid fibrils. This mechanism directly targets the underlying pathophysiology of TTR amyloidosis. As an active pharmaceutical ingredient (API), it is the core substance formulated into the branded drug Vyndaqel� (tafamidis meglumine) capsules and Vyndamax� (tafamidis) tablets. Its development represented a first-in-class, disease-modifying therapy for hereditary and wild-type forms of transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).

Vyndaquel

Tafamidis

Vyndaquel

Vyndaquel 61mg Tablets